Hormone treatment of multiple sclerosis

• US 20050239758A1
• Filed: 04/20/2005
• Published: 10/27/2005
• Est. Priority Date: 04/21/2004
• Status: Abandoned Application

• Current Assignee: Russell R. Roby
• Original Assignee: Russell R. Roby
• Inventors: Roby, Russell R.
• Application Number:
  US11/110,285
• Publication Number:
  US 20050239758A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Abstract

Compositions and/or methods are provided for treating multiple sclerosis and/or an autoimmune condition comprising administering to a human an effective amount of a hormone dilution.

Claims

1. A method for treating multiple sclerosis comprising administering to a human an effective amount of a hormone dilution.

2. The method of claim 1 wherein the hormone dilution comprises a steroid hormone solution with a concentration from about 5 mg/ml to about 0.5 μ

g/ml.

3. The method of claim 1, wherein the hormone dilution comprises a progesterone, an estrogen, or a progesterone and an estrogen.

4. The method of claim 1 further comprising the concentration of the hormone solution selected from the group consisting of 5 mg/ml, 0.5 mg/ml, 50 μ

g/ml, 5 μ

g/ml, and 0.5 μ

g/ml.

5. The method of claim 1 wherein the hormone dilution comprises a progesterone dilution of 10%.

7. The method of claim 1 wherein the hormone dilution is administered sublingually.

8. The method of claim 1 wherein the hormone dilution is administered in a sublingual tablet.

9. The method of claim 1 wherein the hormone dilution is administered as sublingual drops.

10. The method of claim 1 wherein the hormone dilution is administered intradermally.

6. The method of claim 6 further comprising the amount of progesterone administered ranges from between approximately 0.5 mg to approximately 0.05 μ

g per dose.

11. A method of treating multiple sclerosis with a hormone dilution comprising:

administering a dilution of progesterone, the dilution configured to be administered sublingually; and

administering additional dilutions of progesterone as often as necessary to stimulate an effective response.

12. The method of claim 11 wherein the hormone dilution comprises drops.

13. The method of claim 11 wherein the hormone dilution comprises a sublingual tablet.

14. A method of treating an autoimmune disease of the central nervous system with a hormone dilution comprising:

administering a dilution of progesterone, the dilution configured to be administered sublingually; and

administering additional dilutions of progesterone as often as necessary to stimulate an effective response.

15. A method of treating multiple sclerosis using sublingual progesterone dilutions comprising administering the progesterone dilution once a day, the progesterone dilution comprising a sublingual tablet or solution formed of 10% progesterone.

16. The method of claim 15, wherein the daily progesterone dilution administration continues for approximately sixty days.

17. The method of claim 15, wherein serum anti-progesterone antibodies are measured.

18. The method of claim 15 wherein anti-myelin antibodies are measured.

19. A composition for treating multiple sclerosis comprising a progesterone in a concentration ranging from approximately 0.05 μ

g/ml to approximately 5 mg/ml.

20. The composition of claim 19 wherein the progesterone dilution comprises a sublingual tablet.

21. The composition of claim 19 wherein the hormone dilution comprises drops.